New Zealand Markets closed

Serina Therapeutics, Inc. (SER)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
10.56+0.56 (+5.60%)
At close: 03:55PM EDT
10.70 +0.14 (+1.33%)
After hours: 04:05PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.00
Open10.50
Bid4.21 x 1800
Ask16.78 x 1000
Day's range9.77 - 10.90
52-week range5.93 - 31.64
Volume12,255
Avg. volume19,413
Market cap92.841M
Beta (5Y monthly)N/A
PE ratio (TTM)75.43
EPS (TTM)0.14
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation

    HUNTSVILLE, AL, July 18, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the appointment of Dr. Srini Tenjarla as the new Senior Vice President of CMC (Chemistry, Manufacturing, and Controls) and Formulation. Dr. Tenjarla brings over 20 years of extensive experience in drug development to Serina. Dr. Tenjarla joins Serina Therapeutics from

  • GlobeNewswire

    Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse® for Advanced Parkinson’s Disease

    CINCINNATI and HUNTSVILLE, Alabama, May 15, 2024 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug delivery platform and Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its POZ Platform™ to develop and improve efficacy and safety across multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs), tod

  • GlobeNewswire

    Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

    HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today reported financial results for the quarter ended March 31, 2024 and provided business highlights. Recent Highlights ●Advancement of SER-252. The Company is advancing its lead drug candidate, SER-252 (POZ-apomorphine), for the treatment of advanced Parkinson’s Disease. The Company anticipat